OncoMatch/Clinical Trials/NCT06988956
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Is NCT06988956 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nimotuzumab and Tegafur for esophageal squamous cell carcinoma.
Treatment: Nimotuzumab · Tegafur — investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with advanced esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: EGFR monoclonal antibody
Received EGFR mAb and EGFR-TKI within half a year
Cannot have received: EGFR tyrosine kinase inhibitor
Received EGFR mAb and EGFR-TKI within half a year
Lab requirements
Blood counts
HBG ≥90g/L; ANC ≥1.5×10^9/L; PLT ≥80×10^9/L
Kidney function
Plasma Cr ≤1.5 ULN or creatinine clearance (CCr) of 60 ml/min
Liver function
ALT and AST ≤2.5 ULN; ALT and AST 5 ULN; TBIL ≤1.5 ULN
Cardiac function
LVEF low normal value (50%)
Main organ function is normal, that is, meet the following criteria: Blood routine examination: HBG≥90g/L; ANC≥1.5×10^9/L; PLT ≥80×10^9/L; Biochemical examination: ALB≥30g/L; ALT and AST≤2.5ULN; ALT and AST 5 ULN; TBIL≤1.5ULN; Plasma Cr≤1.5ULN or creatinine clearance (CCr) of 60 ml/min; Echocardiographic assessment: left ventricular ejection fraction (LVEF) low normal value (50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06988956 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EGFR monoclonal antibody, EGFR tyrosine kinase inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage II or III or IVA or IVB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages